CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells,Cancer Biology & Therapy

当前位置： X-MOL 学术 › Cancer Biol. Ther. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells
Cancer Biology & Therapy ( IF 3.6 ) Pub Date : 2024-02-15 , DOI: 10.1080/15384047.2024.2314322
Hongjie Wang ₁ , Theo Koob ₁ , Jonathan R. Fromm ₂ , Ajay Gopal ₁ , Darrick Carter ₂ , André Lieber _{1,

2,

3}

Affiliation

Multiple myeloma (MM) is an incurable malignancy of the B-cell lineage. Remarkable progress has been made in the treatment of MM with anti-CD38 monoclonal antibodies such as daratumumab and isatuxi...

中文翻译：

CD46 和 CD59 抑制剂增强抗 CD38 单克隆抗体 daratumumab 和 isatuximab 在多发性骨髓瘤和其他 B 细胞恶性肿瘤细胞中的补体依赖性细胞毒性

多发性骨髓瘤 (MM) 是一种无法治愈的 B 细胞系恶性肿瘤。 daratumumab、isatuxi等抗CD38单克隆抗体在MM治疗方面取得了显着进展...

更新日期：2024-02-17

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>